

MAY 03 2006

CASE PR/4-30970A

DAC  
JEW

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV33671848545

Express Mail Label Number

MAY 2, 2006

Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

CUENOUD ET AL.

Examiner: Kifle, Bruck

APPLICATION NO: 10/009,008

FILED: JANUARY 8, 2002

FOR: BETA2-ADRENOCEPTOR AGONISTS

**MS: Petition**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Attention: Ms. Karin Ferriter  
Senior Legal Advisor**

STATUS REQUEST

Sir:

It is respectfully requested that the status of the Request for Reconsideration of "final" Patent Term Adjustment (PTA) filed on May 24, 2005 be communicated to the undersigned at the U.S. Patent and Trademark Office's (USPTO's) earliest convenience.

Since the subject U.S. patent issued on April 12, 2005, the above-mentioned Request for Reconsideration, a copy of which is attached, was timely filed under 37 CFR 1.705(d). Moreover, it is clear that the Request for Reconsideration was received by the USPTO as evidenced by the return of the stamped postcard, a copy of which is also attached. In said Request for Reconsideration, it was requested that the "final" PTA for USP 6,878,721 be corrected to 130 days. However, since over eleven months have elapsed from the filing of the Request for Reconsideration and no response have been received from the USPTO, the Patentees are concerned that something may have gone amiss, e.g., an "administrative" breakdown may have occurred in the Office of Patent Legal Administration.

In view of the foregoing, it is respectfully requested that the Office of Patent Legal Administration communicate the status of the Request for Reconsideration to the undersigned and if, indeed, no action have been taken, it is respectfully requested that the Request for

Reconsideration be favorably considered and a Certificate of Correction be sent out wherein the "cover" page of the subject U.S. patent reflects a "final" PTA of 130 days.

No fee is believed to be required regarding the instant Status Request. However, if the USPTO deems a fee to be required, please charge it to Deposit Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Date: 5/2/06

Attachs: Copy of Request for Reconsideration  
of "Final" PTA  
Copy of Stamped, Returned Postcard  
Postcard

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV336718600US  
Express Mail Label NumberMay 24, 2005  
Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT OF  
CUENOUD ET AL.

U.S. PATENT NO.: 6,878,721

ISSUED: APRIL 12, 2005

FOR: BETA2-ADRENOCEPTOR AGONISTS

Mail Stop Petition  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450REQUEST FOR RECONSIDERATION OF "FINAL" PATENT TERM ADJUSTMENT  
UNDER 37 CFR 1.705(d)

Sir:

Patentees hereby respectfully request that the "final" Patent Term Adjustment (PTA) for USP 6,878,721 be corrected to 130 days under 37 CFR 1.705(d). The "cover" page of USP 6,878,721, a copy of which is attached, incorrectly lists 94 days.

Since the U.S. Patent and Trademark Office (PTO) did not send out an "initial" Office Action within 14 months of January 8, 2002, i.e., the day that the 35 U.S.C. §371 requirements were fulfilled and, therefore, did not comply with the requirement of 37 CFR 1.703(a)(1), but otherwise complied with the requirement of 37 CFR 1.703(a)(2), and since the patentees did not fail to engage in reasonable efforts to conclude prosecution of the application and, therefore, complied with the requirement of 37 CFR 1.704(b), the "initial" PTA was 81 days.

On the other hand, although the subject U.S. patent issued within 4 months of the date that the Issue Fee was paid and, therefore, the PTO complied with the requirement of 37 CFR 1.703(a)(6), it did not issue within 3 years from the date that the national stage commenced under 35 U.S. §371(b) and, therefore, the requirement of 37 CFR 1.703(b) was not complied with. Moreover, it appears that the PTO inadvertently calculated the "3-year" anniversary date from the date that the 35 U.S.C. §371 requirements were fulfilled, viz., January 8, 2002, rather


than from the date that the national stage commenced, viz., December 3, 2001. In this connection, and with regard to the "national stage" of PCT applications, the PTO 14-month rule contrasts with the PTO 3-year issue guarantee (see the attached appropriate highlighted section of the M.P.E.P.). Accordingly, instead of generating a credit of 130 days, the PTO's calculation incorrectly generated a credit of only 94 days.

In view of the foregoing, and since 37 CFR 1.703(f) precludes overlap beyond the actual number of days that the issuance of the subject U.S. patent was delayed, it is respectfully requested that this Request for Reconsideration be favorably considered and the "cover" page of the subject U.S. patent be corrected to reflect a "final" patent term adjustment of 130 days.

Please charge the \$200 fee required by 37 CFR 1.18(e) and any other fees that may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation. An additional copy of this Request for Reconsideration of "final" PTA is enclosed.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Patentees  
Reg. No. 47,666  
Phone No. (862) 778-2614

Attachs.: "cover" page of USP 6,878,721  
highlighted sections of M.P.E.P.  
extra copy of Request for Reconsideration  
postcard

Date: May 24, 2005



US006878721B1

(12) **United States Patent**  
Cuenoud et al.

(10) Patent No.: **US 6,878,721 B1**  
(45) Date of Patent: **Apr. 12, 2005**

(54) **BETA2-ADRENOCEPTOR AGONISTS**

(75) Inventors: **Bernard Cuenoud, Horsham (GB); Ian Bruce, Horsham (GB); Robin Alec Fairhurst, Horsham (GB); David Beattie, Horsham (GB)**

(73) Assignee: **Novartis AG, Basel (CH)**

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 94 days.

(21) Appl. No.: **10/009,008**

(22) PCT Filed: **Jun. 2, 2000**

(86) PCT No.: **PCT/EP00/05058**

§ 371 (c)(1),  
(2), (4) Date: **Jan. 8, 2002**

(87) PCT Pub. No.: **WO00/75114**

PCT Pub. Date: **Dec. 14, 2000**

(30) **Foreign Application Priority Data**

Jun. 4, 1999 (GB) ..... 9913083

(51) Int. Cl.<sup>7</sup> ..... **C07D 215/26; C07D 215/22; C07D 405/12; A61K 31/395; A61P 43/00**

(52) U.S. Cl. .... **514/312; 514/605; 514/649; 514/657; 546/157; 564/99; 564/123; 564/355; 564/360**

(58) Field of Search ..... **514/312, 605, 514/649, 657; 546/157; 564/99, 123, 355, 360**

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

5,510,376 A 4/1996 Epstein et al. .... 514/463  
5,578,638 A 11/1996 Brazzell et al. .... 514/463  
5,594,027 A 1/1997 Epstein et al. .... 514/463  
5,977,154 A 11/1999 Bell et al. .... 514/394

#### FOREIGN PATENT DOCUMENTS

EP 0 286 278 A1 10/1988  
EP 0 882 704 A1 8/1997  
EP 0 894 787 A1 10/1997

WO WO 92/18461 A1 10/1992  
WO WO 93/15041 A1 8/1993  
WO WO 93 18007 A1 9/1993  
WO WO 99 09001 A1 2/1999  
ZA 987425 8/1998

#### OTHER PUBLICATIONS

Chemical Abstract AN 1994:217308, WO 93 18007, Tsuchiya et al., (1993).


Banitt et al., Monofluoromethanesulfonanilides. A New Series of Bronchodilators, Journal of Medicinal Chemistry, vol. 17, No. 1 (1974).

Primary Examiner—Bruck Kifle


(74) Attorney, Agent, or Firm—Gregory C. Houghton

(57) **ABSTRACT**

Compounds of formula



in free or salt or solvate form, where  
Ar is a group of formula



Y is carbon or nitrogen and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

**19 Claims, No Drawings**

ending on the date of the termination of the suspension.

(2) The period of delay under paragraph (a)(2) of this section for an application is the sum of the following periods, to the extent that the periods are not overlapping:

(i) The number of days, if any, the application was maintained in a sealed condition under 35 U.S.C. 181;

(ii) The number of days, if any, in the period beginning on the date of mailing of an examiner's answer under § 1.193 in the application under secrecy order and ending on the date the secrecy order and any renewal thereof was removed;

(iii) The number of days, if any, in the period beginning on the date applicant was notified that an interference would be declared but for the secrecy order and ending on the date the secrecy order and any renewal thereof was removed; and

(iv) The number of days, if any, in the period beginning on the date of notification under § 5.3(c) and ending on the date of mailing of the notice of allowance under § 1.311.

(3) The period of delay under paragraph (a)(3) of this section is the sum of the number of days, if any, in the period beginning on the date on which an appeal to the Board of Patent Appeals and Interferences was filed under 35 U.S.C. 134 and ending on the date of a final decision in favor of the applicant by the Board of Patent Appeals and Interferences or by a Federal court in an appeal under 35 U.S.C. 141 or a civil action under 35 U.S.C. 145.

(d) The period of delay set forth in paragraph (c)(3) shall be reduced by:

(1) Any time during the period of appellate review that occurred before three years from the filing of the first national application for patent presented for examination; and

(2) Any time during the period of appellate review, as determined by the Director, during which the applicant for patent did not act with due diligence. In determining the due diligence of an applicant, the Director may examine the facts and circumstances of the applicant's actions during the period of appellate review to determine whether the applicant exhibited that degree of timeliness as may reasonably be expected from, and which is ordinarily exercised by, a person during a period of appellate review.

(e) The provisions of this section apply only to original patents, except for design patents, issued on applications filed on or after June 8, 1995, and before May 29, 2000.

[Added, 60 FR 20195, Apr. 25, 1995, effective June 8, 1995; para. (e) added, 65 FR 56366, Sept. 18, 2000, effective Oct. 18, 2000; para. (d)(2) revised, 68 FR 14332, Mar. 25, 2003, effective May 1, 2003; para. (a)(3) revised, 69 FR 21704, Apr. 22, 2004, effective May 24, 2004]

**§ 1.702 Grounds for adjustment of patent term due to examination delay under the Patent Term Guarantee Act of 1999 (original applications, other than designs, filed on or after May 29, 2000).**

(a) *Failure to take certain actions within specified time frames.* Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to the failure of the Office to:

(1) Mail at least one of a notification under 35 U.S.C. 132 or a notice of allowance under 35 U.S.C. 151 not later than fourteen months after the date on which the application was filed under 35 U.S.C. 111(a) or fulfilled the requirements of 35 U.S.C. 371 in an international application;

(2) Respond to a reply under 35 U.S.C. 132 or to an appeal taken under 35 U.S.C. 134 not later than four months after the date on which the reply was filed or the appeal was taken;

(3) Act on an application not later than four months after the date of a decision by the Board of Patent Appeals and Interferences under 35 U.S.C. 134 or 135 or a decision by a Federal court under 35 U.S.C. 141, 145, or 146 where at least one allowable claim remains in the application; or

(4) Issue a patent not later than four months after the date on which the issue fee was paid under 35 U.S.C. 151 and all outstanding requirements were satisfied.

(b) *Failure to issue a patent within three years of the actual filing date of the application.* Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to the failure of the Office to issue a patent within three years after the date on which the application was filed under 35 U.S.C. 111(a) or the national stage commenced

under 35 U.S.C. 371(b) or (f) in an international application, but not including:

- (1) Any time consumed by continued examination of the application under 35 U.S.C. 132(b);
- (2) Any time consumed by an interference proceeding under 35 U.S.C. 135(a);
- (3) Any time consumed by the imposition of a secrecy order under 35 U.S.C. 181;
- (4) Any time consumed by review by the Board of Patent Appeals and Interferences or a Federal court; or
- (5) Any delay in the processing of the application by the Office that was requested by the applicant.

(c) *Delays caused by interference proceedings.* Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to interference proceedings under 35 U.S.C. 135(a).

(d) *Delays caused by secrecy order.* Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to the application being placed under a secrecy order under 35 U.S.C. 181.

(e) *Delays caused by successful appellate review.* Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to review by the Board of Patent Appeals and Interferences under 35 U.S.C. 134 or by a Federal court under 35 U.S.C. 141 or 145, if the patent was issued under a decision in the review reversing an adverse determination of patentability. If an application is remanded by a panel of the Board of Patent Appeals and Interferences and the remand is the last action by a panel of the Board of Patent Appeals and Interferences prior to the mailing of a notice of allowance under 35 U.S.C. 151 in the application, the remand shall be considered a decision by the Board of Patent Appeals and Interferences as that phrase is used in 35 U.S.C. 154(b)(1)(A)(iii), a decision in the review reversing an adverse determination of patentability as that phrase is used in 35 U.S.C. 154(b)(1)(C)(iii), and a final decision in favor of the applicant under § 1.703(e). A remand by a panel of the Board of Patent Appeals and Interferences shall not be considered a decision in the review reversing an adverse determi-

nation of patentability as provided in this paragraph if there is filed a request for continued examination under 35 U.S.C. 132(b) that was not first preceded by the mailing, after such remand, of at least one of an action under 35 U.S.C. 132 or a notice of allowance under 35 U.S.C. 151.

(f) The provisions of this section and §§ 1.703 through 1.705 apply only to original applications, except applications for a design patent, filed on or after May 29, 2000, and patents issued on such applications.

[Added. 65 FR 56366, Sept. 18, 2000, effective Oct. 18, 2000; para. (e) revised. 69 FR 21704, Apr. 22, 2004, effective May 24, 2004]

### § 1.703 Period of adjustment of patent term due to examination delay.

(a) The period of adjustment under § 1.702(a) is the sum of the following periods:

(1) The number of days, if any, in the period beginning on the day after the date that is fourteen months after the date on which the application was filed under 35 U.S.C. 111(a) or fulfilled the requirements of 35 U.S.C. 371 and ending on the date of mailing of either an action under 35 U.S.C. 132, or a notice of allowance under 35 U.S.C. 151, whichever occurs first;

(2) The number of days, if any, in the period beginning on the day after the date that is four months after the date a reply under § 1.111 was filed and ending on the date of mailing of either an action under 35 U.S.C. 132, or a notice of allowance under 35 U.S.C. 151, whichever occurs first;

(3) The number of days, if any, in the period beginning on the day after the date that is four months after the date a reply in compliance with § 1.113(c) was filed and ending on the date of mailing of either an action under 35 U.S.C. 132, or a notice of allowance under 35 U.S.C. 151, whichever occurs first;

(4) The number of days, if any, in the period beginning on the day after the date that is four months after the date an appeal brief in compliance with § 1.192 was filed and ending on the date of mailing of any of an examiner's answer under § 1.193, an action under 35 U.S.C. 132, or a notice of allowance under 35 U.S.C. 151, whichever occurs first;

(5) The number of days, if any, in the period beginning on the day after the date that is four months

Case No. PR14-30970A  
<sup>Patent</sup>  
Application No. 6,878,721  
Mailing Date: May 24, 2005  
Due Date: 6/13/05  
Express Mail No.: EV336718600US

The Patent & Trademark Office acknowledges and has stamped  
hereon the date of receipt of the items checked below:

- ☐ Amendment/Response/Letter - Fee \$  
☐ Appln. Filing Papers - Fee \$  
☐ PCT National Stage  
☐ Provisional Application  
☐ RCE ☐ DIV ☐ CONT ☐ PCT  
☐ Specification  
☐ Executed/Unexecuted Decl. - Fee \$  
☐ Missing Parts/Missing Req.  
☐ Preliminary Amendment Pg's  
☐ Claim of Priority ☐ Certified Copy(s)  
☐ Amendment After Final  
☐ Notice of Appeal - Fee \$  
☐ Appeal Brief - Fee \$  
☐ Issue Fee Payment \$  
☐ Assignment Rec. Req. - Fee \$  
☐ Formal Drawings Pg's  
☐ IDS Pg's - Fee \$  
☐ PTO-1449 Form Pg's  
☐ Pet. for Ext. of Time - Fee \$  
☐ Application Data Sheet  
☐ Seq. Listings Pg's/Seq. Disk  
☒ Request for Reconsideration of "Final" PTA

GCH  
Initials

- (1) "cover" page of USP 6,878,721  
(2) highlighted section of MPEP  
(3) extra copy of Request for Reconsideration  
82972/99A Rev.1

JUN 2005  
RECEIVED  
Linda C. Rothwell  
Patent

MAY 24 2005

fee \$200.00